Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

NCT04473716 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Oral Cancer
Induction Chemotherapy
Programmed Cell Death 1 Inhibitor
Inductive Therapy

Interventions

DRUG: Toripalimab
DRUG: Paclitaxcel
DRUG: Cisplatin
PROCEDURE: Radical surgery
RADIATION: Post-operative radiotherapy/chemoradiotherapy

Sponsor

Shanghai Jiao Tong University School of Medicine